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CC BY-NC-ND license (http://creativeAbstract iPSCs hold great promise in that a large quantity of cardiomyocytes (iPSC-CM) can
be generated and cultured in vitro for clinical purposes. These cells are currently being sub-
jected to vigorous testing in animal transplantation models to ascertain their survivability
and functional integration in the injured heart. So far, most of those studies have been con-
ducted in small animals and sometimes in xenogeneic settings, and have produced mixed re-
sults. Representing a step forward, a recent study in Nature reported the transplantation of
MHC-matched allogeneic monkey iPSC-CM. This was the first time iPSC-CM have been tested
in a non-human primate model in an allogeneic setting, which is the next best thing to a human
clinical trial.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).“Mending a broken heart is never easy,” or so the saying
goes. This is probably also true in the case of acute
myocardial infarction due to a clogged coronary artery.
Although there is presently no specific treatment aimed at
regenerating damaged cardiac muscle, the void is being
rapidly filled, as shown by the recent developments using
induced pluripotent stem cells (iPSCs). iPSCs are derived
from adult tissue cells, and are transformed into pluripo-
tent stem cells through genetic reprogramming. iPSCs hold
great promise in that a large quantity of cardiomyocytes
(iPSC-CM) can be generated and cultured in vitro for clinicals.org.
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commons.org/licenses/by-nc-nd/purposes. These cells are currently being subjected to
vigorous testing in animal transplantation models to
ascertain their survivability and functional integration in
the injured heart.1,2 So far, most of those studies have been
conducted in small animals and sometimes in xenogeneic
settings, and have produced mixed results. Representing a
step forward, a recent study in Nature reported the
transplantation of MHC-matched allogeneic monkey iPSC-
CM.3 This was the first time iPSC-CM have been tested in a
non-human primate model in an allogeneic setting, which is
the next best thing to a human clinical trial. In that study,
the authors first generated iPSC-CM using homozygous iPSC
cells from cynomolgus monkeys. Homozygous stem cells
have the advantage of an increased likelihood of a histo-
compatibility match. These homozygous iPSC-CM cells wereand hosting by Elsevier B.V. This is an open access article under the
4.0/).
240 F. Lithen transplanted into MHC-matched heterozygous mon-
keys modeling acute myocardial infarction. Through 12
weeks of post-transplantation observation and analysis, the
authors of that study were able to show successful
engraftment/survival of implanted iPSC-CM in the damaged
heart. These implants were able to couple electrically and
mechanically with the host cardiac muscle, which resulted
in improved cardiac contraction. Another encouraging
finding was that none of the five recipient animals devel-
oped tumors, which has been widely feared considering the
highly proliferative potential of IPSC stem cells. However,
as observed in other previous transplantation studies, all
five recipient monkeys developed episodes of idioven-
tricular arrhythmia. Fortunately, these episodes subsided in
the later stage, and the recipient animals seemed to be
symptom-free by the end of the study. Nevertheless, the
engrafted cardiac muscles presented an immature pheno-
type with low expression of cardiomyocyte-specific pro-
teins as well as a slow propagation of cardiac electric waves
as suggested in previous in vitro research.2 Since the post-
transplantation analyses were only performed for 12weeks, extended follow-up studies are warranted to
investigate whether the cardiac engrafts can survive long-
term, and whether they eventually mature to exhibit an
appropriate phenotype.Conflict of interest
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